Johnson & Johnson Highlights Neuropsychiatry Leadership with New Data at APA and ASCP
Event summary
- Johnson & Johnson will present 18 abstracts at the APA and ASCP Annual Meetings in May 2026, showcasing data from its neuropsychiatry portfolio.
- Key presentations include long-term data on CAPLYTA for schizophrenia relapse prevention and Phase 3 studies on seltorexant for MDD with insomnia symptoms.
- The company highlights its commitment to addressing residual symptoms in neuropsychiatric conditions through innovative treatments.
- Poster presentations will cover SPRAVATO's role in relapse prevention for treatment-resistant depression and recommendations for long-acting injectables in schizophrenia.
The big picture
Johnson & Johnson's focus on neuropsychiatry aligns with the growing need for innovative treatments in mental health, particularly for conditions like schizophrenia and treatment-resistant depression. The company's deep portfolio and pipeline underscore its strategic commitment to addressing unmet needs in this complex and rapidly evolving field. The presentations at APA and ASCP will provide critical insights into the efficacy and safety of its leading therapies, potentially influencing market dynamics and regulatory pathways.
What we're watching
- Pipeline Progress
- The success of seltorexant in Phase 3 studies will determine its potential approval and market positioning in treating MDD with insomnia symptoms.
- Market Differentiation
- Whether CAPLYTA's long-term data can solidify its role in schizophrenia relapse prevention and expand its market share.
- Regulatory Landscape
- The pace at which regulatory approvals for new neuropsychiatric treatments will impact Johnson & Johnson's competitive edge.
Related topics